[1] Zhang Jianjun Liu Wenzhou Ou Li,.Clinical Study on Treatment of Hyperlipidemia with Hongxing Pill and Its Effects on TNF - ɑ, IL -6 and ET -1 [J]. Modern Traditional Chinese Medicine, 2019, (02): 96-100. [doi: 10.13424/j.cnki.mtcm.2019.02.029]
Clinical Study on Treatment of Hyperlipidemia with Hongxing Pill and Its Effects on TNF - ɑ, IL -6 and ET -1
- Article number:
- 1672-0571(2019)02-0096-05
- ZTFLH:
- R589.2
- Code:
- A
- Abstract:
- To explore the clinical efficacy of Hongxing Pill in the treatment of hyperlipidemia and its effects on tumor necrosis factor ( TNF - ɑ) , interleukin -6 ( IL -6) and endothelin -1 ( ET -1) . Method A randomized, double - blind, parallel - controlled trial design method was used to randomize 112 patients with hyperlipidemia who were included in our hospital from September to October 2017 according to a 1: 1 ratio. The treatment group and the control group each had 56 cases. The treatment group was given Hongxing Pills, and the control group was given a placebo for 60 days. In the course of the experiment, there were 4 cases failed in the treatment group and 5 cases in the control group. Finally, there were 52 cases in the treatment group and 51 cases in the control group. After the blindness was uncovered, the therapeutic effect of Hongxing Pill on hyperlipidemia and its influence on TNF - _, IL -6 and ET -1 were analyzed. Result The effective rates of total cholesterol, triglyceride and high density lipoprotein in the treatment group were 59. 62%, 55. 77% and 51. 92%, significantly higher than those in the placebo control group ( 9. 80%, 3. 92% and 19. 61%) . TC and TG values in the treatment group were significantly lower than those in the control group, while HDL- C value was significantly higher than that in the control group. ET -1 and inflammatory factors TNF - _and IL -6 were lower than those in the placebo control group, with statistical significance. Conclusion Hongxing Pill can not only effectively regulate the blood lipid level of patients with hyperlipidemia, but also protect vascular endothelial function and improve inflammation by reducing TNF - _, IL -6 and ET -1.
References:
[1]孙芳,尚文斌.中医药治疗高脂血症的研究进展[J].中医药信息,2011,28(2):120-123.
[2]晓勇.高血脂症的危害及预防[N].健康报,2002-06-04(004).
[3]黄震华,徐济民.高脂血症治疗进展[J].上海预防医学,2003,15(5):210-213.
[4]王晓书,唐媛媛,孙易红.血府逐瘀胶囊治疗气滞血瘀型高脂血症的临床研究[J].中药药理与临床,2017,33(5):177-180.
[5]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007;19(5):390-419.
[6]唐娟,王德芳,徐艳,等.缺血后处理对高脂血症大鼠脑缺血再灌注后脑组织TNF-ɑ和SOCS-3表达的影响[J].山东医药,2016,56(37):38-40.
[7]周子严,薛晓琳,李鑫,等.从痰瘀论治血脂异常的文献研究[J].中华中医药杂志,2018,33(4):1485-1488.
[8]陈富荣,章怡,刘萍.痰瘀互结型高脂血症主要中医症状的分布特点[J].中华中医药学刊,2009,27(12):2508-2510.
[9]赵水平.调脂药物概述[J].中南药学,2011,9(1):68-71.
[10]袁文姬.合用他汀类药物不良反应的分析[J].中国医药导报,2011,8(3):119,121.
[11]赵水平.烟酸类调脂药物研究进展[J].临床药物治疗杂志,2010,8(2):5-8.
[12]吴文静,柯元南,郑金刚.新型降脂药-依折麦布的研究进展[J].心血管病学进展,2009,30(4):558-561.
[13]张惠芳,黄之训.功能红曲生理活性作用机制和治疗保健功效[J].中华医学与健康,2007,4(2):77-79.
[14]刘杰,张燕,鲍进方,等.脂必妥治疗飞行员高血脂症的临床研究[J].中国疗养医学,2008,17(5):310-311.
[15]温学伟,马新,周立平,等.红曲抗氧化的研究进展[J].食品工业科技,2011,32(2):376-378.
[16]吴沁.银杏叶调节血脂和抗氧化作用研究[J].江苏预防医学,2010,21(6):10-12.
[17]何星篧,刘臖,罗春,等.银杏叶治疗高脂血症的网络药理学研究[J].中国医院药学杂志,2016,36(10):787-791.
[18] Adibhatla RM, Hatcher JF. Secretory phospholipase A2 ⅡA is up - regulated by TNF - ɑ and IL -1ɑ/ βafter transient focal cerebral is - chemia in rat[ J] . Brain Res,2007,1134( 1) :199 -205.
[19] Boyle K, Zhang J, Nicholson S, et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 ( SOCS3) in embryonic stemcells reveals SOCS box - dependent regulation
of JAK but not STAT phosphorylation [ J] . Cell Sign,2009,21( 3) :394 -404.
[20]熊伟平,边长勇.瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂炎性介质及内皮指标的影响[J].山西医药杂志,2017,46(23):2909-2911.
Memo
基金项目：陕西省秦岭中草药应用开发工程技术研究中心项目（２００８ＺＤＧＣ－３２）